Details
Stereochemistry | RACEMIC |
Molecular Formula | C20H17F3N2O4 |
Molecular Weight | 406.3552 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OCC(O)COC(=O)C1=C(NC2=C3C=CC=C(C3=NC=C2)C(F)(F)F)C=CC=C1
InChI
InChIKey=APQPGQGAWABJLN-UHFFFAOYSA-N
InChI=1S/C20H17F3N2O4/c21-20(22,23)15-6-3-5-13-17(8-9-24-18(13)15)25-16-7-2-1-4-14(16)19(28)29-11-12(27)10-26/h1-9,12,26-27H,10-11H2,(H,24,25)
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/23755755Curator's Comment: description was created based on several sources, including, https://www.aapharma.ca/downloads/en/PIL/2014/Floctafenine_PM.pdf
Sources: http://www.ncbi.nlm.nih.gov/pubmed/23755755
Curator's Comment: description was created based on several sources, including, https://www.aapharma.ca/downloads/en/PIL/2014/Floctafenine_PM.pdf
Floctafenine is an analgesic agent used for the treatment of pain. The drug exerts its anti-inflammatory action by inhibiting COX-1 and COX-2, with a slight preference towards COX-1. Floctafenine is marketed in Canada under the name Floctafenine and it is withdrawn in Europe (Idarac Brand name).
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P23219|||Q5T7T7 Gene ID: 5742.0 Gene Symbol: PTGS1 Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/23755755 |
2.33 mM [IC50] | ||
Target ID: P35354 Gene ID: 5743.0 Gene Symbol: PTGS2 Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/23755755 |
3.47 mM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | FLOCTAFENINE Approved UseFLOCTAFENINE (floctafenine) is indicated for short-term use in acute pain of mild and moderate severity. |
PubMed
Title | Date | PubMed |
---|---|---|
[Ionized fluorine in the plasma and urine of subjects treated with organofluorine drugs prescribed in rheumatology]. | 1979 Feb |
|
Intracranial hypertension with etretinate. | 1983 Oct 22 |
|
[Identification of a metabolite of floctafenine in urinary calculi]. | 1987 |
|
Leukotriene receptor antagonists may prevent NSAID-induced exacerbations in patients with chronic urticaria. | 2000 Aug |
|
Determination of thiocolchicoside in its binary mixtures (thiocolchicoside-glafenine and thiocolchicoside-floctafenine) by TLC-densitometry. | 2003 Jun |
|
Absolute contraindications in relation to potential drug interactions in outpatient prescriptions: analysis of the first five million prescriptions in 1999. | 2003 Nov |
|
Absolute contraindications in relation to potential drug interactions in outpatient prescriptions: analysis of the first five million prescriptions in 1999. | 2004 Feb |
|
Synthesis of some floctafenine derivatives of expected anti-inflammatory/analgesic activity. | 2005 Aug |
|
Oral aspirin challenges in patients with a history of intolerance to single non-steroidal anti-inflammatory drugs. | 2005 Jun |
|
Differential pulse cathodic voltammetric determination of floctafenine and metopimazine. | 2007 Mar 12 |
|
Clinical management of adult patients with a history of nonsteroidal anti-inflammatory drug-induced urticaria/angioedema: update. | 2007 Mar 15 |
|
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
Sample Use Guides
The usual adult dose of floctafenine is 200 to 400 mg every 6 to 8 hours as required. The maximum recommended daily dose is 1200 mg.
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/23755755
The effects of floctafenine and its active metabolite on platelet COX-1, monocyte and 5-LO activities of whole blood in vitro were assessed by incubating increasing concentrations of floctafenine or floctafenic acid (0.001-100 mM) with peripheral whole blood samples drawn from healthy volunteers.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C257
Created by
admin on Sat Dec 16 17:32:54 UTC 2023 , Edited by admin on Sat Dec 16 17:32:54 UTC 2023
|
||
|
WHO-VATC |
QN02BG04
Created by
admin on Sat Dec 16 17:32:54 UTC 2023 , Edited by admin on Sat Dec 16 17:32:54 UTC 2023
|
||
|
WHO-ATC |
N02BG04
Created by
admin on Sat Dec 16 17:32:54 UTC 2023 , Edited by admin on Sat Dec 16 17:32:54 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C80553
Created by
admin on Sat Dec 16 17:32:54 UTC 2023 , Edited by admin on Sat Dec 16 17:32:54 UTC 2023
|
PRIMARY | |||
|
DB08976
Created by
admin on Sat Dec 16 17:32:54 UTC 2023 , Edited by admin on Sat Dec 16 17:32:54 UTC 2023
|
PRIMARY | |||
|
m5405
Created by
admin on Sat Dec 16 17:32:54 UTC 2023 , Edited by admin on Sat Dec 16 17:32:54 UTC 2023
|
PRIMARY | Merck Index | ||
|
3360
Created by
admin on Sat Dec 16 17:32:54 UTC 2023 , Edited by admin on Sat Dec 16 17:32:54 UTC 2023
|
PRIMARY | |||
|
100000080996
Created by
admin on Sat Dec 16 17:32:54 UTC 2023 , Edited by admin on Sat Dec 16 17:32:54 UTC 2023
|
PRIMARY | |||
|
Floctafenine
Created by
admin on Sat Dec 16 17:32:54 UTC 2023 , Edited by admin on Sat Dec 16 17:32:54 UTC 2023
|
PRIMARY | |||
|
23779-99-9
Created by
admin on Sat Dec 16 17:32:54 UTC 2023 , Edited by admin on Sat Dec 16 17:32:54 UTC 2023
|
PRIMARY | |||
|
SUB07645MIG
Created by
admin on Sat Dec 16 17:32:54 UTC 2023 , Edited by admin on Sat Dec 16 17:32:54 UTC 2023
|
PRIMARY | |||
|
1178
Created by
admin on Sat Dec 16 17:32:54 UTC 2023 , Edited by admin on Sat Dec 16 17:32:54 UTC 2023
|
PRIMARY | |||
|
2936
Created by
admin on Sat Dec 16 17:32:54 UTC 2023 , Edited by admin on Sat Dec 16 17:32:54 UTC 2023
|
PRIMARY | |||
|
DTXSID8057695
Created by
admin on Sat Dec 16 17:32:54 UTC 2023 , Edited by admin on Sat Dec 16 17:32:54 UTC 2023
|
PRIMARY | |||
|
O04HVX6A9Q
Created by
admin on Sat Dec 16 17:32:54 UTC 2023 , Edited by admin on Sat Dec 16 17:32:54 UTC 2023
|
PRIMARY | |||
|
CHEMBL2105075
Created by
admin on Sat Dec 16 17:32:54 UTC 2023 , Edited by admin on Sat Dec 16 17:32:54 UTC 2023
|
PRIMARY | |||
|
C084600
Created by
admin on Sat Dec 16 17:32:54 UTC 2023 , Edited by admin on Sat Dec 16 17:32:54 UTC 2023
|
PRIMARY | |||
|
245-881-4
Created by
admin on Sat Dec 16 17:32:54 UTC 2023 , Edited by admin on Sat Dec 16 17:32:54 UTC 2023
|
PRIMARY | |||
|
4444
Created by
admin on Sat Dec 16 17:32:54 UTC 2023 , Edited by admin on Sat Dec 16 17:32:54 UTC 2023
|
PRIMARY | RxNorm |
ACTIVE MOIETY
METABOLITE (PARENT)